Researchers at VIB-KU Leuven have discovered that interrupting lipid signaling between brain immune cells and tumor cells reduces the invasive spread of glioblastoma. Published in Cancer Cell, the study outlines a potential preoperative strategy to make these aggressive primary brain tumors more contained.
In Plain English: The Clinical Takeaway
- Targeting Communication: Instead of attacking the tumor’s genetic mutations directly, the new approach blocks the chemical signals passed between brain immune cells and cancer cells.
- Limiting Spread: By stopping microglia from releasing specific fatty molecules, researchers successfully kept tumor cells from invading healthy surrounding brain tissue.
- Surgical Implications: Because complete tumor removal is the strongest predictor of survival, containing the cancer before surgery could eventually help extend patient lifespans.
Cellular Communication Pathways in Glioblastoma Invasion
Glioblastoma stands as the most aggressive primary brain tumor in adults. Patients face a median patient survival of about 15 months. Treating the condition remains exceptionally difficult because malignant cells infiltrate surrounding healthy brain tissue. This invasive behavior prevents neurosurgeons from achieving a total resection, which serves as the strongest predictor of survival.
To investigate how this invasion occurs, researchers at the VIB-KU Leuven Center for Cancer Biology, led by Professor Gabriele Bergers, focused on microglia, the resident immune cells of the brain. Microglia typically promote glioblastoma progression by secreting growth-promoting proteins. While scientists understood that immune cells aided tumor growth, the specific role played by lipids—or fatty molecules—remained largely unexplored until now.
Using mouse models and tissue from glioblastoma patients, the research team tracked how tumor cells interact with these fats. They discovered that cancer cells utilize lipids released by microglia to increase their mobility. This mechanism drives the cells deeper into healthy brain regions.
According to Dr. Carla Pallarés-Moratalla, first author at the VIB-KU Leuven Center for Cancer Biology, the team observed that microglia secrete lysophosphatidic acids (LPAs)—a specialized category of lipids—which attach to tumor cells and trigger pathways promoting their migration into distant regions of the brain.
Interrupting Lipid Signaling Preoperatively
Building on their discovery of LPA signaling, the research team tested whether blocking this cellular dialogue could alter tumor behavior. By intervening in the communication pathway, scientists made the tumors less invasive in experimental models.
We were able to interrupt these signals and make tumors less invasive. Although the size of the tumor did not change, these results raise the possibility of treating patients before surgery to make their tumors more contained and easier to remove. Because this approach limits spread but does not shrink the tumor, it could be combined with therapies that reduce tumor size, which could further improve patient survival.
Dr. Carla Pallarés-Moratalla
To validate these findings beyond animal models, the investigators examined human samples. Tests performed on patient-derived tumor cell lines demonstrated that human immune cells promote invasion through the exact same lipid pathway observed in mice. Professor Gabriele Bergers noted that the findings could translate to patients.
| Research Parameter | Observed Impact |
|---|---|
| Target Mechanism | Microglial lipid signaling (Lysophosphatidic acids / LPAs) |
| Tumor Response | Reduced cellular invasion without altering overall tumor volume |
| Clinical Implication | Potential preoperative containment to facilitate complete surgical resection |
Because glioblastoma tumors exhibit high levels of heterogeneity, distinct regions within an individual patient’s tumor can harbor unique mutations. Because this novel therapeutic strategy targets intercellular communication rather than specific genetic mutations, researchers believe it could apply to a broader spectrum of glioblastoma cases.
Contraindications & When to Consult a Doctor
These findings remain in an early stage of research. Patients currently undergoing treatment for glioblastoma must not alter standard regimens, as these discoveries have not yet yielded approved clinical therapies or pharmacological interventions for human use.
References
- Pallarés-Moratalla, C., et al. (2026). Macrophage lipid signaling drives glioblastoma invasion and represents a therapeutic vulnerability. Cancer Cell. DOI: 10.1016/j.ccell.2026.10.006
